PMID- 35156731
OWN - NLM
STAT- MEDLINE
DCOM- 20220517
LR  - 20220731
IS  - 1600-0609 (Electronic)
IS  - 0902-4441 (Print)
IS  - 0902-4441 (Linking)
VI  - 108
IP  - 6
DP  - 2022 Jun
TI  - Impact of infectious comorbidity and overall time of hospitalization in total 
      outpatient management of acute myeloid leukemia patients following venetoclax and 
      hypomethylating agents.
PG  - 449-459
LID - 10.1111/ejh.13753 [doi]
AB  - Venetoclax (VEN) and hypomethylating agent (HMAs) regimens are emerging as the 
      standard of care for unfit for chemotherapy acute myeloid leukemia (AML) 
      patients, but the safety and feasibility of a total outpatient management have 
      not been fully investigated. Fifty-nine AML patients with active disease received 
      VEN and HMAs. Nineteen out of 59 (32.2%) patients received the first cycle as 
      inpatients, whereas 40/59 (67.8%) patients were treated in the outpatient 
      setting. No significant differences were observed with regard to incidence of 
      adverse events (AEs), including tumor lysis syndrome (TLS), and the 30-day and 
      60-day mortality was comparable. Notably, an infectious prophylaxis inspired to 
      that adopted during intensive chemotherapy resulted in a low infection rate with 
      a reduced bacterial infections incidence in out- versus hospitalized patients 
      (p < .0001). The overall time of hospitalization was significantly shorter in 
      patients who received a total outpatient treatment as compared to those who 
      received the first cycle as inpatients (5.9 vs. 39.7 days, p < .0001). Despite 
      the adopted differences in treatment management, the efficacy was similar. These 
      data indicate that a total outpatient management of VEN and HMAs is feasible in 
      AML patients without negatively impacting on treatment efficacy and may yield 
      pharmacoeconomic and quality-of-life benefits.
CI  - (c) 2022 The Authors. European Journal of Haematology published by John Wiley & 
      Sons Ltd.
FAU - Papayannidis, Cristina
AU  - Papayannidis C
AD  - IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 
      "Seragnoli", Bologna, Italy.
FAU - Nanni, Jacopo
AU  - Nanni J
AD  - Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Universita di 
      Bologna, Bologna, Italy.
FAU - Cristiano, Gianluca
AU  - Cristiano G
AD  - Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Universita di 
      Bologna, Bologna, Italy.
FAU - Marconi, Giovanni
AU  - Marconi G
AD  - IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, 
      Italy.
FAU - Sartor, Chiara
AU  - Sartor C
AD  - Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Universita di 
      Bologna, Bologna, Italy.
FAU - Parisi, Sarah
AU  - Parisi S
AD  - IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 
      "Seragnoli", Bologna, Italy.
AD  - Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Universita di 
      Bologna, Bologna, Italy.
FAU - Zannoni, Letizia
AU  - Zannoni L
AD  - Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Universita di 
      Bologna, Bologna, Italy.
FAU - Saed, Rashed
AU  - Saed R
AD  - Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Universita di 
      Bologna, Bologna, Italy.
FAU - Ottaviani, Emanuela
AU  - Ottaviani E
AD  - IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 
      "Seragnoli", Bologna, Italy.
FAU - Bandini, Lorenza
AU  - Bandini L
AD  - Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Universita di 
      Bologna, Bologna, Italy.
FAU - Testoni, Nicoletta
AU  - Testoni N
AD  - IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 
      "Seragnoli", Bologna, Italy.
AD  - Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Universita di 
      Bologna, Bologna, Italy.
FAU - Baldazzi, Carmen
AU  - Baldazzi C
AD  - IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 
      "Seragnoli", Bologna, Italy.
FAU - Solli, Vincenza
AU  - Solli V
AD  - Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Universita di 
      Bologna, Bologna, Italy.
FAU - Ricci, Paolo
AU  - Ricci P
AD  - Assistenza Domiciliare AIL Bologna, Bologna, Italy.
FAU - Di Giovanni Bezzi, Chiara
AU  - Di Giovanni Bezzi C
AD  - Assistenza Domiciliare AIL Bologna, Bologna, Italy.
FAU - Abd-Alatif, Rania
AU  - Abd-Alatif R
AD  - Assistenza Domiciliare AIL Bologna, Bologna, Italy.
FAU - Stanzani, Marta
AU  - Stanzani M
AD  - IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 
      "Seragnoli", Bologna, Italy.
FAU - Paolini, Stefania
AU  - Paolini S
AD  - IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 
      "Seragnoli", Bologna, Italy.
FAU - Cavo, Michele
AU  - Cavo M
AD  - IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 
      "Seragnoli", Bologna, Italy.
AD  - Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Universita di 
      Bologna, Bologna, Italy.
FAU - Curti, Antonio
AU  - Curti A
AD  - IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 
      "Seragnoli", Bologna, Italy.
LA  - eng
PT  - Journal Article
DEP - 20220228
PL  - England
TA  - Eur J Haematol
JT  - European journal of haematology
JID - 8703985
RN  - 0 (Bridged Bicyclo Compounds, Heterocyclic)
RN  - 0 (Sulfonamides)
RN  - N54AIC43PW (venetoclax)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - Bridged Bicyclo Compounds, Heterocyclic
MH  - Comorbidity
MH  - Hospitalization
MH  - Humans
MH  - *Leukemia, Myeloid, Acute/complications/drug therapy/epidemiology
MH  - *Outpatients
MH  - Sulfonamides
PMC - PMC9314138
OTO - NOTNLM
OT  - Venetoclax
OT  - acute myeloid leukemia
OT  - hospitalization
OT  - hypomethylating agents
OT  - infections
OT  - outpatient
OT  - real life
COIS- Dr. Cristina Papayannidis received honoraria from Pfizer, Amgen, and Novartis. 
      Dr. Antonio Curti received honoraria from Novartis, Pfizer, and Abbvie and acted 
      as speaker in Advisory Board for Novartis and Abbvie. Prof. Michele Cavo acted as 
      consultant for and received honoraria from AbbVie, Glaxo Smith Kline, 
      Bristol-Myers Squib, Adaptive Biotechnologies, Takeda, Janssen, Celgene, and 
      Amgen. Moreover, Prof. Cavo is in the speaker's bureau of AbbVie and Glaxo Smith 
      Kline. The other authors declare no conflict of interest or activities that could 
      appear to have influenced this manuscript.
EDAT- 2022/02/15 06:00
MHDA- 2022/05/18 06:00
PMCR- 2022/07/25
CRDT- 2022/02/14 09:18
PHST- 2022/02/05 00:00 [revised]
PHST- 2021/10/19 00:00 [received]
PHST- 2022/02/07 00:00 [accepted]
PHST- 2022/02/15 06:00 [pubmed]
PHST- 2022/05/18 06:00 [medline]
PHST- 2022/02/14 09:18 [entrez]
PHST- 2022/07/25 00:00 [pmc-release]
AID - EJH13753 [pii]
AID - 10.1111/ejh.13753 [doi]
PST - ppublish
SO  - Eur J Haematol. 2022 Jun;108(6):449-459. doi: 10.1111/ejh.13753. Epub 2022 Feb 
      28.